Advice

following a full submission assessed under the orphan equivalent process:

ruxolitinib phosphate (JakaviĀ®) is accepted for use within NHSScotland.

Indication under review: The treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea (hydroxycarbamide).

Ruxolitinib was superior to best available therapy in two phase III studies in patients with polycythaemia vera who were resistant to or intolerant of hydroxycarbamide, with or without splenomegaly.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a list price that is equivalent or lower.

This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.

Medicine details

Medicine name:
ruxolitinib (Jakavi)
SMC ID:
SMC2213
Indication:

The treatment of adult patients with polycythaemia vera (PV) who are resistant to or intolerant of hydroxyurea (HU).

Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Full
Status
Accepted
Date advice published:
09 December 2019